RxDoctor Payments Data

Richard Male, DO

Family Medicine · Georgetown, TXNPI 1134129596

Payments from drug & device makers

$2,003in general payments, 2019–2025

Across 69 payments — averaging $29.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$529
  • AbbVie$298
  • Merck$280
  • Astellas Pharma US Inc$174
  • Johnson & Johnson$167
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$119
  • plus $436 from 11 others

What the payments were for

  • Food & beverage$1,90395%
  • Education$1005%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,003 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$119,770
Medicare patients
282
Services billed
1,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide63$77,656
EliquisApixaban39$52,185
JardianceEmpagliflozin27$36,244
TrulicityDulaglutide27$32,468
MounjaroTirzepatide24$31,983
XareltoRivaroxaban15$20,373
Breo ElliptaFluticasone/Vilanterol11$7,088
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$5,473
SymbicortBudesonide/Formoterol Fumarate17$5,353
Gabapentin203$3,725
Atorvastatin Calcium371$3,437
Levothyroxine Sodium346$3,420
Rosuvastatin Calcium261$3,131
Testosterone18$3,053
Duloxetine Hcl118$2,841

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$14$77,65663 claims
Johnson & JohnsonXarelto$167$20,37315 claims
GSKBreo Ellipta$112$7,08811 claims
AstraZenecaSymbicort$529$5,35317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Georgetown

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →